Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

MONTE ROSA THERAPEUTICS INC (GLUE)

162 + Investors. Track Smart Money conviction in GLUE. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +33
Streak
7Q ▲
Buyers last Q
66%

Smart Money Signals — GLUE

Based on 158 hedge funds · latest filing: 2025 Q4 · updated quarterly

📈

Buying streak — 7 quarters in a row

last 6Q
For 7 consecutive quarters, more hedge funds added GLUE than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
158 hedge funds hold GLUE right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +50% more funds vs a year ago

fund count last 6Q
+53 new funds entered over the past year (+50% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 66% buying

106 buying54 selling
Last quarter: 106 funds were net buyers (50 opened a brand new position + 56 added to an existing one). Only 54 were sellers (37 trimmed + 17 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+25 vs last Q)

new funds entering per quarter
Funds opening a new GLUE position: 24 → 25 → 25 → 50. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
📌

Mixed — 34% long-term, 39% new

■ 34% conviction (2yr+) ■ 28% medium ■ 39% new
Of the 158 current holders: 53 (34%) held >2 years, 44 held 1–2 years, and 61 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💎

Buying through price weakness — shares +8%, value -38%

Value
-38%
Shares
+7%
Last quarter: funds added +8% more shares while total portfolio value only changed -38%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
🚀

Acceleration phase — new buyers rushing in

35 → 24 → 25 → 25 → 50 new funds/Q
New funds entering each quarter: 24 → 25 → 25 → 50. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Deep conviction — 43% of holders stayed 2+ years

■ 43% veterans ■ 7% 1-2yr ■ 50% new
Of 165 current holders: 71 (43%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
✅

Strong quality — 27% AUM from major funds

27% from top-100 AUM funds
44 of 158 holders rank in the top 100 by AUM, accounting for 27% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.6
out of 10
Moderate Exit Risk
Exit risk score 4.6/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — GLUE

In 2025 Q4, 106 hedge funds were net buyers of GLUE (50 opened a new position, 56 added to an existing one), while 54 reduced or exited (37 trimmed, 17 sold completely) — a 66% buyer ratio, indicating clear institutional accumulation. This marks 7 consecutive quarters of net institutional buying — a persistent conviction signal. 27% of total institutional value in GLUE is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +33 funds (more new holders than closures). Total institutional holders: 158.

Hedge Fund Ownership: GLUE

How many hedge funds hold GLUE — quarterly history vs. share price
Quarterly hedge fund ownership of GLUE vs. share price

Market Analysis: GLUE

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: GLUE

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy MONTE ROSA THERAPEUTICS INC (GLUE) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much GLUE has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 49d ago
GLUE
+19.6%
XLV
-11.8%

GLUE outperformed XLV by +31.4% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 4d ago
GLUE
-0.8%
XLV
-5.2%

Since the filing became public, GLUE outperformed XLV by +4.4% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

31 top-rated funds 2 high-conviction
Consensus
6.5
/ 10
breadth
×
Elite
2.6
/ 10
conviction
Hedge Fund Positioning: GLUE
2026 Q1 Stats Unlock in 1 days 162 + Investors

Track Smart Money conviction in GLUE. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2025 Q4) Prior (2025 Q3) Change
Funds Holding 162 129 25.58%
13F Shares 65M 60M 7.49%
Total Value $939M $1.51B -37.98%
New Positions 50 27 +23
Increased Positions 63 38 +25
Closed Positions 17 14 +3
Reduced Positions 50 44 +6
Total Calls 4 3 33.33%
Total Puts 3 3 -
PUT/CALL Ratio 0.75 1.0 Neutral

Statistics: GLUE

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

162 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in GLUE. Verified SEC 13F-HR filings.

QUARTER:
Top 25 institutional holders of GLUE — 2025 Q4 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Versant Venture Management, LLC 37.00% 3,180,780 $52.3M
2 NEA Management Company, LLC 7.19% 7,692,298 $126.5M
3 Aisling Capital Management LP 5.37% 1,555,664 $25.6M
4 SILVERARC CAPITAL MANAGEMENT, LLC 3.36% 2,002,040 $32.9M
5 BVF INC/IL 2.34% 4,460,886 $73.4M
6 TCG Crossover Management, LLC 2.18% 4,622,151 $76.0M
7 SUVRETTA CAPITAL MANAGEMENT, LLC 1.78% 4,226,809 $69.5M
8 BRAIDWELL LP 1.76% 3,206,574 $52.7M
9 Vestal Point Capital, LP 1.66% 3,603,465 $59.3M
10 Exome Asset Management LLC 1.53% 179,484 $3.0M
11 MPM BioImpact LLC 1.50% 1,176,928 $19.4M
12 Parkwood LLC 0.74% 505,000 $8K
13 DIADEMA PARTNERS LP 0.52% 187,307 $3.1M
14 Bellevue Group AG 0.49% 1,250,000 $20.6M
15 Rangeley Capital, LLC 0.43% 27,016 $444K
16 Frazier Life Sciences Management, L.P. 0.42% 1,000,000 $16.4M
17 BAKER BROS. ADVISORS LP 0.41% 4,345,736 $71.5M
18 Nantahala Capital Management, LLC 0.39% 651,993 $10.7M
19 Nextech Invest, Ltd. 0.35% 304,237 $5.0M
20 Cormorant Asset Management, LP 0.33% 400,000 $6.6M
21 PSP Research LLC 0.33% 28,000 $461K
22 Persistent Asset Partners Ltd 0.29% 47,500 $781K
23 ACT CAPITAL MANAGEMENT, LLC 0.29% 22,500 $370K
24 Alphabet Inc. 0.28% 684,275 $11.3M
25 Informed Momentum Co LLC 0.25% 130,246 $2.1M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — MONTE ROSA THERAPEUTICS INC (GLUE)

What does the Smart Money Trend signal show for GLUE?

Buying streak — 7 quarters in a row: For 7 consecutive quarters, more hedge funds added GLUE than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for GLUE?

More buyers than sellers — 66% buying: Last quarter: 106 funds were net buyers (50 opened a brand new position + 56 added to an existing one). Only 54 were sellers (37 trimmed + 17 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for GLUE holders?

Strong quality — 27% AUM from major funds: 44 of 158 holders rank in the top 100 by AUM, accounting for 27% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held GLUE?

Mixed — 34% long-term, 39% new: Of the 158 current holders: 53 (34%) held >2 years, 44 held 1–2 years, and 61 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy MONTE ROSA THERAPEUTICS INC (GLUE) following the 2026 Q1 hedge fund 13F filings?

As of today, GLUE has moved -0.8% since the 2026 Q1 13F filing date (May 15, 2026), compared to -5.2% for the XLV sector ETF — an outperformance of +4.4%. Since the quarter end (March 31, 2026), GLUE has gained +19.6% vs -11.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.